Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
New chief financial officers at Alector, CanSino, and more.
Novartis gets new People And Organization Officer, plus new CEOs at BerGenBio, Pillar Biosciences, Pascal Biosciences, Jubilant and Civetta Therapeutics.
Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.
Aamir Malik leaves McKinsey & Co to join Pfizer as chief business innovation officer and executive vice president.
Some 22 years after founding what was one of the biggest success stories in Europe's biotech sector before a recent series of setbacks in the clinic struck, Onno van de Stolpe has decided to retire as Galapagos CEO and the search has already started for his successor.
Former Tmunity Therapeutics CFO Simona King joins Passage Bio as CFO. Rune Skeie, CFO of BerGenBio, holds the fort as interim CEO until Martin Olin joins in September.
Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Gorsky is stepping down due to a family health issue.
Adagene gets new chief medical officer, while Corcept Therapeutics gets new chief development officer from Gilead.
Oncology leader Anne White will oversee neuroscience and pain, while Bio-Medicines head Ilya Yuffa will take over for retiring Lilly International president; Loxo CEO will oversee entire oncology business.
New chief financial officers at Quiapeg Pharmaceuticals and Trevi Therapeutics.
Some big pharma R&D leaders have signaled enhanced interest in neuroscience R&D – and Alzheimer's more specifically – following FDA's approval of Biogen's Aduhelm based on biomarkers.
New chief medical officers at IGM Biosciences, Compass Pathways, Passage Bio and more.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.